Skin cancer is the leading cause of malignancy in the United States, with Basal Cell Carcinoma, Squamous Cell
Carcinoma, and Melanoma being the three most common diagnoses, respectively. Squamous Cell Carcinoma (SCC) is a
particular concern for patients suffering from Dystrophic Epidermolysis Bullosa (DEB), a disease that affects the
production and function of collagen VII, a protein that forms the anchoring fibrils which bind the epidermis to the dermis.
Patients with DEB suffer from chronic blistering and wounds that have impaired healing capabilities, often leading to the
development of SCC and eventual mortality. Nanomedicine is playing an increasing role in the delivery of effective
therapeutics to combat a wide range of diseases, including the imaging and treatment of SCC. In this review, we discuss
the role of nanoparticles in the treatment of SCC with an emphasis on PLGA nanoparticles and SCCs found in patients
suffering from DEB, and address recent patents that are pertinent to the development of novel nanomedical therapeutics.
Keywords: Bullosa, carcinoma, dystrophic, EGFR, epidermolysis squamous, nanomedicine, nanoparticles, p53, PLGA.
Rights & PermissionsPrintExport